Dosing of Mood Stabilizers for Bipolar Disorder Patients in the Research on Asian Psychotropic Prescription Patterns Consortium Study

Yuxi Wang, Qian Hui Chew, Shih Ku Lin, Shu Yu Yang, Wen Chen Ouyang, Chih Ken Chen, Seon Cheol Park, Ok Jin Jang, Jun Hyuk Park, Kok Yoon Chee, Kwong Sen Ding, Jamaline Chong, Ling Zhang, Keqing Li, Xiaomin Zhu, Chonnakarn Jatchavala, Pornjira Pariwatcharakul, Roy Abraham Kallivayalil, Sandeep Grover, Ajit AvasthiMoin Ansari, Margarita M. Maramis, Paing Phyo Aung, Norman Sartorius, Yu Tao Xiang, Chay Hoon Tan, Mian Yoon Chong, Yong Chon Park, Takahiro A. Kato, Naotaka Shinfuku, Ross J. Baldessarini, Kang Sim

Research output: Contribution to journalArticlepeer-review

Abstract

Background Because use and dosing of mood stabilizers (MSs) to treat bipolar disorder (BD) patients in Asia are not well documented, we examined prevalence and clinical correlates of treatment of Asian BD patients with relatively high doses of MSs. Methods We conducted a pharmacoepidemiological survey across 13 Asian countries and territory in the Research on Asian Psychotropic Prescription Patterns Consortium. Mood stabilizer doses were converted to lithium carbonate equivalents (Li-eq milligrams per day). We compared relatively high (>900 Li-eq mg/day) versus lower MS doses by bivariate comparisons, followed by multivariable linear regression to identify factors associated with higher MS doses. Results Among 1647 participants, MS dose averaged 584 (confidence interval, 565-603 Li-eq mg/d). Preliminarily, the 13.1% of the subjects given greater than 900 mg/d versus those given lower doses were younger, male, currently hospitalized, not currently depressed, and reported lifetime suicidal ideation; they also received relatively high doses of antipsychotics, received electroconvulsive treatment within the previous 12 months, and had greater ratings of tremors and sedation. By linear regression modeling, the mean proportion given high doses of MS was associated significantly and independently with higher doses of antipsychotics, younger age, male sex, hospitalized, more years of illness, country, higher body mass index, recent electroconvulsive treatment, and being in illness remission. Conclusions Relatively high doses of MSs for BD are prevalent, but vary markedly among Asian countries, and are particularly likely among young males, ill for many years, and given high doses of antipsychotics or ECT. These characteristics allow better identification of patient profiles that can guide treatment of BD patients.

Original languageEnglish
Pages (from-to)293-297
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume42
Issue number3
DOIs
Publication statusPublished - May 1 2022

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Dosing of Mood Stabilizers for Bipolar Disorder Patients in the Research on Asian Psychotropic Prescription Patterns Consortium Study'. Together they form a unique fingerprint.

Cite this